Patent ID: 6432963
Filing Date: 2002-08-13
Classification: A61P,C07D

Abstract:
A pyrimidine-5-carboxamide derivative represented by a formula (I) or a salt thereof wherein each symbol has the following meaning;X: O; S; NR1; CO; NR1CO; CONR1; C&boxH;Nâ€”OR1 or a bond, Y: a lower alkylene group which may be substituted by OR1 or â€”NHR1; or a bond, Z: O or NR2, A: H; or a lower alkyl which may have from 1 to 4 substituent(s) selected from Group a or Group c; a â€”CO-lower alkyl which may have from 1 to 4 substituent(s) selected from Group a or Group c; an aryl which may have from 1 to 4 substituent(s) selected from Group a or Group b; a five- to eight-membered monocyclic heteroaryl group which (i) has from 1 to 4 hetero atoms selected from O, S, and N and (ii) may have from 1 to 4 substituent(s) selected from Group a or Group b; a cycloalkyl which may have from 1 to 4 substituent(s) selected from Group a; or a five- to eight-membered saturated heterocyclic group which (i) has at least one N as a ring atom, (ii) may have one O or S as a ring atom, and (iii) may have from 1 to 4 substituent(s) selected from Group a, B: an aryl which may have from 1 to 4 substituent(s) selected from Group a or Group b or a five- to eight-membered monocyclic heteroaryl group which (i) has from 1 to 4 hetero atoms selected from O, S, and N and (ii) may have from 1 to 4 substituent(s) selected from Group a or Group b, and R1, R2: H; a lower alkyl or â€”CO-lower alkyl group, Group a: â€”NH2; â€”NH2 in a prodrug form; -lower alkylene-NH2; -lower alkylene-NH2 in a prodrug form; â€”NH-lower alkyl; â€”N(lower alkyl)2; â€”NH-lower alkylene-aryl; â€”NH-aryl; â€”NH-cycloalkyl; â€”NH-a five- to eight-membered monocyclic heteroaryl group which has from 1 to 4 hetero atoms selected from O, S, and N; â€”NHCO-lower alkyl; â€”NHSO2-lower alkyl; â€”NHC(NH)NH2; â€”NHCONH2; â€”OH; â€”O-lower alkyl; â€”CO2H; â€”CONHOH; â€”CO2-lower alkyl; â€”CONH-lower alkyl; or â€”CON(lower alkyl)2, Group b: -lower alkyl; -halogen atom selected from the group consisting of F, Cl, Br, and I; -lower alkyl having One or more hydrogen atoms substituted by a halogen atom selected from the group consisting of F, Cl, Br, and I; â€”O-lower alkylene-aryl; â€”O-aryl; â€”O-lower alkylene-aryl-O-lower alkyl; â€”S-lower alkylene-aryl; â€”S-lower alkylene-aryl-O-lower alkyl; â€”NO2; or â€”CN, and Group c: -halogen atom selected from the group consisting of F, Cl, Br, and I; â€”O-lower alkylene-aryl, â€”O-aryl; â€”O-lower alkylene-aryl-O-lower alkyl; â€”S-lower alkylene-aryl; â€”S-lower alkylene-aryl-O-lower alkyl; â€”NO2; â€”CN; -aryl which may be substituted by a group selected from Group a; -cycloalkyl; -a five- to eight-membered monocyclic heteroaryl group which has from 1 to 4 hetero atoms selected from 0, S, and N; -a five- to eight-membered saturated heterocyclic group having from 1 to 4 hetero atoms selected from O, S, and N; -vinyl; -(1-propenyl); or -ethynyl, â€ƒwith the proviso that A is a group other than an ethyl group when X is NH, Y and Z are respectively a bond and B is 2-methylphenyl, and wherein â€”NH2 in the prodrug form means a group selected from the group consisting of (Z)-3-{2-(acetoxy)phenyl}-2-propenoylanino-, (acetoxy)rnethoxycarbonylamino-, 4-azidobenzyloxycarbonylamino-, (5-methyl-2-oxo-1,3-dioxol-4-en-4-yl)methoxycarbonylamino-, and {(2-hydroxyphenyl)(phenyl)methylidene}amino-.